(Q36544945)

14 August 2017

1 reference

title

Screening the receptorome reveals molecular targets responsible for drug-induced side effects: focus on 'fen-phen'. (English)

1 reference

14 August 2017

0 references

Vincent Setola

1

1 reference

PubMed ID

16863450

14 August 2017

Bryan L Roth

series ordinal

2

1 reference

PubMed ID

16863450

14 August 2017

language of work or name

English

0 references

publication date

1 October 2005

1 reference

Expert Opinion on Drug Metabolism & Toxicology

14 August 2017

1 reference

14 August 2017

1

1 reference

14 August 2017

3

1 reference

14 August 2017

377-387

1 reference

In vitro receptor screening of pure constituents of St. John's wort reveals novel interactions with a number of GPCRs

14 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.377

Effect of antidepressants on GABA(B) receptor function and subunit expression in rat hippocampus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.377

Finding the Intracellular Signaling Pathways Affected by Mood Disorder Treatments

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.377

Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.377

Monoaminergic synapses and schizophrenia: 45 years of neuroleptics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.377

Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.377

21 January 2018

Mining the receptorome

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.377

Salvinorin A: a potent naturally occurring nonnitrogenous kappa opioid selective agonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.377

Salvinorin A: the "magic mint" hallucinogen finds a molecular target in the kappa opioid receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.377

The human polyomavirus, JCV, uses serotonin receptors to infect cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.377

N-desmethylclozapine, an allosteric agonist at muscarinic 1 receptor, potentiates N-methyl- d -aspartate receptor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.377

The highly efficacious actions of N-desmethylclozapine at muscarinic receptors are unique and not a common property of either typical or atypical antipsychotic drugs: is M1 agonism a pre-requisite for mimicking clozapine's actions?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.377

International trial of long-term dexfenfluramine in obesity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.377

Effects of dexfenfluramine on resting metabolic rate and thermogenesis in premenopausal obese women during therapeutic weight reduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.377

Dexfenfluramine in obese Chinese NIDDM patients. A placebo-controlled investigation of the effects on body weight, glycemic control, and cardiovascular risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.377

Haemodynamic, metabolic and endocrine effects of short-term dexfenfluramine treatment in young, obese women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.377

Comparison of continuous and intermittent anorectic therapy in obesity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.377

Long-term weight control study. II (weeks 34 to 104). An open-label study of continuous fenfluramine plus phentermine versus targeted intermittent medication as adjuncts to behavior modification, caloric restriction, and exercise

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.377

Long-term weight control study. I (weeks 0 to 34). The enhancement of behavior modification, caloric restriction, and exercise by fenfluramine plus phentermine versus placebo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.377

Valvular heart disease associated with fenfluramine-phentermine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.377

Prevalence and clinical determinants of mitral, tricuspid, and aortic regurgitation (the Framingham Heart Study)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.377

The prevalence of cardiac valvular insufficiency assessed by transthoracic echocardiography in obese patients treated with appetite-suppressant drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.377

An assessment of heart-valve abnormalities in obese patients taking dexfenfluramine, sustained-release dexfenfluramine, or placebo. Sustained-Release Dexfenfluramine Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.377

Valvular abnormalities and cardiovascular status following exposure to dexfenfluramine or phentermine/fenfluramine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.377

Fenfluramine and phentermine and cardiovascular findings: effect of treatment duration on prevalence of valve abnormalities

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.377

Effect of fenfluramine-derivative diet pills on cardiac valves: a meta-analysis of observational studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.377

Histologic changes in three explanted native cardiac valves following use of fenfluramines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.377

Autopsy findings of heart and lungs in a patient with primary pulmonary hypertension associated with use of fenfluramine and phentermine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.377

Serotonin 2B receptor is required for heart development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.377

Ablation of serotonin 5-HT(2B) receptors in mice leads to abnormal cardiac structure and function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.377

5-hydroxytryptamine 2B receptor regulates cell-cycle progression: cross-talk with tyrosine kinase pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.377

Ras involvement in signal transduction by the serotonin 5-HT2B receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.377

3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.377

Differential regulation of chondrogenic differentiation by the serotonin2B receptor and retinoic acid in the embryonic mouse hindlimb

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.377

Valvular heart disease in patients taking pergolide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.377

Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.377

Pergolide use in Parkinson disease is associated with cardiac valve regurgitation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.377

Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. III. Agonist and antagonist properties at serotonin, 5-HT(1) and 5-HT(2), receptor subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.377

Severe multivalvular heart disease: a new complication of the ergot derivative dopamine agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.377

Fibrotic valvular heart disease subsequent to bromocriptine treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.377

Repeated doses administration of MDMA in humans: pharmacological effects and pharmacokinetics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.377

Function of the serotonin 5-hydroxytryptamine 2B receptor in pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.377

Nordexfenfluramine causes more severe pulmonary vasoconstriction than dexfenfluramine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.377

The fenfluramine metabolite (+)-norfenfluramine is vasoactive

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.377

Serotonin transporter inhibition prevents and reverses monocrotaline-induced pulmonary hypertension in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.377

Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.377

Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.377

Attenuated hypoxic pulmonary hypertension in mice lacking the 5-hydroxytryptamine transporter gene.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.377

H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.377

In vitro characterization of ephedrine-related stereoisomers at biogenic amine transporters and the receptorome reveals selective actions as norepinephrine transporter substrates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.377

L-homocysteine sulfinic acid and other acidic homocysteine derivatives are potent and selective metabotropic glutamate receptor agonists.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.377

A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.377

21 January 2018

Identifiers

DOI

10.1517/17425255.1.3.377

1 reference

14 August 2017

1 reference

PubMed ID

16863450